Inivata Announces Strategic Partnership with West Cancer Center
West Cancer Center joins the Inivata Knowledge Accumulation Network (IKAN)
Inivata, a global clinical cancer genomics company utilizing an industry-leading liquid biopsy platform to transform patient care, today announces a strategic partnership with West Cancer Center that will see the organisation join the Inivata Knowledge Accumulation Network (IKAN).
The IKAN is a global network of world-leading cancer centers working in partnership with Inivata to assess the potential of liquid biopsy to transform cancer care and improve patient outcomes.
Lee S. Schwartzberg MD, FACP, Medical Oncologist and Haematologist at West Cancer Center, said:
“We are delighted to be partnering with the world-class team at Inivata and joining the IKAN, Inivata’s novel concept to unite global experts in oncology to accelerate research into the potential of ctDNA analysis to improve treatment decisions and patient outcomes. We look forward to working with Inivata and the other members of the IKAN network in the development of Inivata’s innovative and highly sensitive InVision™ liquid biopsy platform.”
Clive Morris, Chief Medical Officer of Inivata, said:
“We are excited to welcome the West Cancer Center, a world-leading cancer institution, to the IKAN. Together we will work on a number of projects involving a broad range of indications to develop and validate our InVision liquid biopsy platform. We believe that the sharing of knowledge between world-leaders is crucial for the continued advancement of the field.”
Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood draw to guide and personalize cancer treatment, monitor response and detect relapse. Inivata’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge. Its lead product, InVisionFirst®-Lung is commercially available and offers best-in-class sensitivity and turnaround, providing molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata has also launched the personalized RaDaR™ assay – allowing the highly sensitive detection of residual disease and recurrence. Inivata is partnering with pharmaceutical, biotechnology companies and commercial partners in a range of early and late stage cancer development programs. The Company has a CLIA certified, CAP accredited laboratory in Research Triangle Park, NC and R&D laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.